Palazestrant, Fulvestrant, Anastrozole, Letrozole — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advan
Phase 3 · Breast Cancer, Advanced Breast Cancer |
OLMA Olema Pharmaceuticals, Inc. | Palazestrant, Fulvestrant, Anastrozole, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|